Nuplazid Launched for Parkinson's Disease Psychosis

Nuplazid becomes the first agent in a new class called selective serotonin inverse agonists
Nuplazid becomes the first agent in a new class called selective serotonin inverse agonists

Acadia announced the launch of Nuplazid (pimavanserin) tablets for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. 

Nuplazid is the first agent in a new class called selective serotonin inverse agonists (SSIA) as well as the first drug to be approved for this indication. Nuplazid preferentially targets 5-HT2A receptors—and to a lesser extent at the serotonin 5-HT2C receptors—while avoiding activity at dopamine and other receptors commonly targeted by antipsychotics. This mechanism does not impair motor function as it does not interfere with patients' dopaminergic therapy. 

Related Articles

The FDA approval in April 2016 was based on data from the Phase 3 study (Study -020) that demonstrated significant reductions in the severity and frequency of hallucinations and delusions in patients with Parkinson's disease psychosis without worsening the primary motor symptoms of Parkinson's disease. It was also previously granted Breakthrough Therapy designation as well as Priority Review by the FDA.

Nuplazid is available as 17mg strength tablets in 60-count bottles. 

For more information call (844) 422-2342 or visit Nuplazid.com.

Loading links....